Novartis Not Nervous About SGLT2 Threat To Entresto

Cardiovascular Blockbuster Closing In On $4-$5bn Sales Guidance

 
• By Kevin Grogan
  
frontrunner
Novartis expects Entresto to continue setting the pace in heart failure • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapeutic Category